Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study
- PMID: 14524484
- DOI: 10.1016/s0936-6555(03)00093-1
Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study
Abstract
Introduction: We compare the cytoreductive efficacy of bicalutamide or goserelin with no hormonal manipulation in prostate cancer before brachytherapy.
Materials and methods: Transrectal ultrasound volume estimations were performed in clinic and during the brachytherapy-planning scan. Between volume estimations, patients received no hormonal treatment, bicalutamide 150 mg once daily or goserelin 3.6 mg every 28 days.
Results: Patients receiving no hormonal manipulation had a volume increase of 8% compared with an 8% volume reduction in the bicalutamide group and a 26% reduction in the goserelin group. As initial prostate volume was not equivalent in the three groups, a subgroup analysis was performed on patients who received active treatment for more than 3 months who had initial prostate volume less than 55 cm3. In this subgroup, a mean fall in prostate volume of 7%, occurred in the bicalutamide group compared with 21% in the goserelin group. In both the original and subgroup analysis, the cytoreductive efficacy of goserelin was significantly greater than bicalutamide (P < 0.0001).
Conclusion: In the absence of data from randomised trials, comparing the efficacy of these agents, luteinising hormone-releasing hormone (LHRH) analogues remain the gold standard for cytoreduction before prostate brachytherapy. If the neoadjuvant efficacy of hormonal manipulation in external beam radiotherapy is dependent on prostate volume reduction, then LHRH analogues may also prove more effective in this neoadjuvant role.
Comment in
-
The role of hormone therapy as a neoadjuvant to radical prostate radiotherapy.Clin Oncol (R Coll Radiol). 2003 Sep;15(6):316-7. doi: 10.1016/s0936-6555(03)00117-1. Clin Oncol (R Coll Radiol). 2003. PMID: 14524483 No abstract available.
Similar articles
-
Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide.Clin Oncol (R Coll Radiol). 2013 Mar;25(3):190-6. doi: 10.1016/j.clon.2012.09.010. Epub 2012 Dec 17. Clin Oncol (R Coll Radiol). 2013. PMID: 23257248 Clinical Trial.
-
Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.BJU Int. 2012 Dec;110(11):1721-8. doi: 10.1111/j.1464-410X.2012.11107.x. Epub 2012 Apr 13. BJU Int. 2012. PMID: 22500884 Clinical Trial.
-
Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.Urology. 1996 Jan;47(1A Suppl):54-60; discussion 80-4. doi: 10.1016/s0090-4295(96)80010-0. Urology. 1996. PMID: 8560679 Clinical Trial.
-
Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.Urol Int. 2014;93(2):152-9. doi: 10.1159/000356272. Epub 2014 Mar 1. Urol Int. 2014. PMID: 24603064 Review.
-
Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development.Prostate. 1998 Jan 1;34(1):61-72. doi: 10.1002/(sici)1097-0045(19980101)34:1<61::aid-pros8>3.0.co;2-n. Prostate. 1998. PMID: 9428389 Review.
Cited by
-
Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months.J Clin Pathol. 2007 Apr;60(4):443-6. doi: 10.1136/jcp.2006.040311. Epub 2006 Jul 5. J Clin Pathol. 2007. PMID: 16822873 Free PMC article. Clinical Trial.
-
Neoadjuvant versus Concurrent Androgen Deprivation Therapy in Localized Prostate Cancer Treated with Radiotherapy: A Systematic Review of the Literature.Cancers (Basel). 2023 Jun 27;15(13):3363. doi: 10.3390/cancers15133363. Cancers (Basel). 2023. PMID: 37444473 Free PMC article. Review.
-
Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments.Br J Cancer. 2011 Nov 22;105(11):1628-34. doi: 10.1038/bjc.2011.385. Epub 2011 Oct 18. Br J Cancer. 2011. PMID: 22009028 Free PMC article. Review.
-
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.Cochrane Database Syst Rev. 2014 Jun 30;2014(6):CD009266. doi: 10.1002/14651858.CD009266.pub2. Cochrane Database Syst Rev. 2014. PMID: 24979481 Free PMC article. Review.
-
A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.BMC Cancer. 2016 Sep 1;16(1):708. doi: 10.1186/s12885-016-2737-8. BMC Cancer. 2016. PMID: 27586506 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
